Proactive Investors
10 Jan 2026, 17:27 UTC · 36w ago
Verdict
Headline takes no side. We score IMUX +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
The phase 2 CALLIPER study for vidofludimus calcium showed a 31% reduction in confirmed disability worsening in progressive MS patients.
So whatStrong positive clinical data in a high-unmet-need area (progressive MS) is a primary driver for biotech valuation and regulatory progress.
More positive than 99% of claims this week
Immunic has strengthened the patent position for vidofludimus calcium, with potential exclusivity extending to 2041 in key markets.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 93% of claims this week
Long-term EMPhASIS study data showed 92.3% of relapsing-remitting MS patients remained free of 12-week confirmed disability worsening after 144 weeks.
More positive than 86% of claims this week
Early findings on IMU-856 in celiac disease indicate an increase in natural GLP-1 levels, suggesting potential applications in weight management.
More positive than 78% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company reported positive phase 2 clinical data showing a significant reduction in disability worsening for MS patients and expanded its patent exclusivity to 2041.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
7h ago
+40.5%
Price agrees with the score
$9.35 vs $6.65 close before publication (Jan 9) · not market-adjusted
IMUX chart →
